📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-30 18:13
666 analysed today
666
Today
133,555
All-time analysed
40,122
Positive
6,284
Negative
79,331
Neutral
7,750
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
11 announcements match the current filters (relevance ≥ 5).
Paushak Q1 FY27: Revenue Jumps 49.5% YoY to ₹83.55 Cr; PAT Up 25.5%
Paushak Limited delivered a strong performance for the quarter ended June 30, 2026, with revenue from operations surging 49.5% YoY to ₹83.55 Cr. Net profit grew 25.5% YoY to ₹15.10 Cr, despite a sharp 167% increase in raw material costs. The quarterly revenue is highly significant, representing approximately 38% of the company's total TTM revenue of ₹219 Cr. This scale-up suggests that the company's ₹240 Cr capacity expansion is beginning to reflect in the top-line performance.
Confidence: HIGH
What changedThe company has achieved a significant step-up in quarterly revenue, moving from a historical range of ₹49-59 Cr to over ₹83 Cr.
Why it mattersThis performance validates the company's expansion strategy and its ability to capture 'China Plus One' demand in the niche phosgene-based specialty chemicals market.
Revenue (Q1 FY27): ₹83.55 CrPAT (Q1 FY27): ₹15.10 CrRevenue vs TTM Revenue: 38.1%YoY Revenue Growth: 49.5%YoY PAT Growth: 25.5%
📅 Short termThe stock is likely to react positively in the short term due to the substantial revenue beat and profit growth compared to historical averages.
📈 Long termThe structural shift toward higher volumes through capacity expansion is evident; long-term value will depend on maintaining margins while scaling semi-specialized products.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Sharp increase in raw material costs (up 167% YoY)
- Potential margin compression from lower-margin semi-specialized products
- Regulatory risks associated with phosgene gas manufacturing
Key Highlights
Revenue from operations increased to ₹83.55 Cr, up 49.5% from ₹55.88 Cr in the same quarter last year.
Net Profit (PAT) rose to ₹15.10 Cr compared to ₹12.03 Cr in Q1 FY26.
Cost of materials consumed spiked to ₹28.99 Cr from ₹10.86 Cr YoY, indicating higher volume or input cost pressure.
Earnings Per Share (EPS) improved to ₹6.13 from a restated ₹4.88 in the year-ago period.
Quarterly revenue of ₹83.55 Cr is ~38% of the previous TTM revenue of ₹219 Cr.
👀 What to Watch
Investors should monitor the sustainability of this higher revenue run-rate and observe if operating margins stabilize as the company integrates its new downstream capacities.
49.5% YoY Revenue Growth to ₹83.55 Cr; Paushak Q1 PAT Rises to ₹15.10 Cr
Paushak Limited reported a robust Q1 FY27 with revenue from operations surging 49.5% YoY to ₹83.55 Cr, significantly exceeding the previous four-quarter average of approximately ₹55 Cr. Net profit grew 25.5% YoY to ₹15.10 Cr, even as depreciation and finance costs rose sharply to ₹8.42 Cr and ₹1.36 Cr respectively, reflecting the capitalization of its ₹240 Cr expansion project. Operating margins remained healthy at approximately 30.7%, an improvement over the TTM average of 27.9%. EPS for the quarter stood at ₹6.13, compared to ₹4.88 in the corresponding quarter of the previous year.
Confidence: HIGH
What changedThe company has achieved a significant scale-up in quarterly revenue, moving from a steady range of ₹50-60 Cr to over ₹80 Cr in Q1 FY27.
Why it mattersThis performance validates the company's ₹240 Cr organic growth strategy and its ability to leverage its unique regulatory moat in phosgene-based chemistry to capture 'China Plus One' demand.
Revenue (Q1 FY27): ₹83.55 CrRevenue vs TTM Revenue: 38.1%PAT (Q1 FY27): ₹15.10 CrYoY Revenue Growth: 49.5%Depreciation (Q1 FY27): ₹8.42 CrFinance Costs (Q1 FY27): ₹1.36 Cr
📅 Short termThe stock is likely to react positively to the strong top-line beat and the maintenance of high operating margins despite increased interest and depreciation costs.
📈 Long termStructural growth remains tied to the successful ramp-up of the ₹240 Cr expansion and the company's ability to maintain its niche leadership in phosgene derivatives.
⚠ Risk flags
- Sharp increase in finance costs indicating higher debt servicing
- Potential margin dilution from lower-margin semi-specialized products
- Sensitivity to chlorine supply and global chemical pricing
Key Highlights
Revenue from operations grew 49.5% YoY to ₹83.55 Cr from ₹55.88 Cr.
Net Profit (PAT) increased 25.5% YoY to ₹15.10 Cr from ₹12.03 Cr.
Depreciation expense rose 107% YoY to ₹8.42 Cr, signaling significant new capacity commissioning.
Finance costs increased to ₹1.36 Cr from just ₹0.04 Cr in the year-ago period.
Earnings Per Share (EPS) improved to ₹6.13 from ₹4.88 YoY.
👀 What to Watch
Watch for management commentary on the utilization levels of the new ₹240 Cr downstream capacity and whether the current 30%+ operating margins are sustainable as the product mix shifts toward semi-specialized products.
Paushak Ltd FY26 Net Profit Rises 25.5% to ₹49.38 Cr; Declares ₹2.50 Dividend
Paushak Limited reported a strong financial performance for the year ended March 31, 2026, with annual revenue growing 26.7% to ₹210.95 crore. Net profit for the full year increased to ₹49.38 crore from ₹39.33 crore in the previous fiscal, reflecting healthy operational growth. The company maintained its profitability in Q4 with a PAT of ₹12.51 crore compared to ₹9.60 crore in the same quarter last year. Additionally, the Board has recommended a dividend of ₹2.50 per share, rewarding shareholders for the strong annual performance.
Key Highlights
Annual Revenue from Operations increased by 26.7% YoY to ₹210.95 crore
Full-year Net Profit (PAT) grew by 25.5% to ₹49.38 crore from ₹39.33 crore
Earnings Per Share (EPS) rose to ₹20.03 for FY26 compared to ₹15.95 in FY25
Recommended a dividend of ₹2.50 per equity share (50% of face value ₹5)
Total Comprehensive Income for the year stood at ₹67.68 crore
👀 What to Watch
The company demonstrates robust double-digit growth in both revenue and profitability along with a consistent dividend payout. Investors should maintain a positive outlook given the strong EPS growth and healthy balance sheet.
Paushak Ltd to Appoint Jain Parkash as Whole-time Director for 3-Year Term
Paushak Limited has initiated a Postal Ballot process to seek shareholder approval for the appointment of Mr. Jain Parkash as a Whole-time Director. The proposed appointment is for a period of three years, effective from April 1, 2026. This is a Special Resolution, requiring a 75% majority for approval. Shareholders can cast their votes electronically between March 19, 2026, and April 17, 2026, with results expected by April 19, 2026.
Key Highlights
Proposed appointment of Mr. Jain Parkash as Whole-time Director for a 3-year tenure starting April 1, 2026.
The resolution is a Special Resolution, necessitating high shareholder consensus.
E-voting period is set from March 19, 2026 (09:00 AM) to April 17, 2026 (05:00 PM).
The cut-off date for determining voting eligibility was March 13, 2026.
Final voting results will be announced on or before April 19, 2026.
👀 What to Watch
Investors should review the appointee's professional background in the explanatory statement to assess leadership quality. No immediate portfolio action is required as this is a standard governance procedure.
Paushak Ltd Appoints Jain Parkash as Whole-time Director; COO Chintan Gosaliya Resigns
Paushak Limited has announced a leadership transition effective from the end of the 2025-26 fiscal year. Mr. Chintan Gosaliya will resign as Whole-time Director and COO on March 31, 2026, to pursue outside opportunities. To ensure continuity, the board has appointed Mr. Jain Parkash, the current Sr. VP of Operational Excellence, as a Whole-time Director for a three-year term starting April 1, 2026. Mr. Parkash brings over 30 years of specialized experience in specialty chemicals and pharma APIs to the role.
Key Highlights
Mr. Chintan Gosaliya to step down as Whole-time Director and COO on March 31, 2026.
Mr. Jain Parkash appointed as Whole-time Director for a 3-year term effective April 1, 2026.
New appointee Mr. Parkash has 30+ years of experience in Specialty Chemicals and Agro-Chemicals.
The appointment is an internal promotion and remains subject to shareholder approval via Special Resolution.
👀 What to Watch
Investors should monitor the transition for any shifts in operational strategy, though the internal promotion of an experienced executive suggests a focus on continuity.
Paushak Ltd Appoints Jain Parkash as Whole-time Director; Chintan Gosaliya Resigns as COO
Paushak Limited has announced a leadership transition where Mr. Chintan Gosaliya will resign as Whole-time Director and COO effective March 31, 2026. To fill the vacancy, the Board has approved the appointment of Mr. Jain Parkash as an Additional and Whole-time Director for a three-year term starting April 1, 2026. Mr. Parkash is currently the Sr. Vice President of Operational Excellence and brings over 30 years of experience in Specialty Chemicals and Pharma API. This internal promotion suggests a focus on operational continuity and leveraging deep industry expertise.
Key Highlights
Mr. Chintan Gosaliya to step down as WTD and COO on March 31, 2026, to pursue outside opportunities.
Mr. Jain Parkash appointed as Whole-time Director for a 3-year term effective April 1, 2026.
Incoming director Mr. Jain Parkash has over 30 years of experience in Specialty Chemicals, Agro-Chemicals, and Pharma API.
The appointment is subject to shareholder approval through a Special Resolution.
Mr. Parkash also serves as a Non-Executive Director on the Board of Alembic Limited.
👀 What to Watch
Investors should monitor the transition for any impact on operational efficiency, though the internal promotion of an experienced industry veteran is generally a stabilizing signal. No immediate action is required as the transition is scheduled for 2026.
Paushak Ltd Appoints Jain Parkash as Whole-time Director; Chintan Gosaliya Resigns as COO
Paushak Limited has announced a leadership transition where Mr. Chintan Gosaliya will resign as Whole-time Director and COO effective March 31, 2026. To ensure continuity, the board has appointed Mr. Jain Parkash, currently the Sr. VP of Operational Excellence, as a Whole-time Director for a three-year term starting April 1, 2026. Mr. Parkash brings over 30 years of extensive experience in Specialty Chemicals and Pharma APIs, which are critical sectors for the company. This internal promotion indicates a focus on maintaining operational stability and leveraging internal expertise for future growth.
Key Highlights
Mr. Chintan Gosaliya to resign as Whole-time Director and COO effective March 31, 2026.
Mr. Jain Parkash appointed as Whole-time Director for a 3-year term starting April 1, 2026.
New appointee Mr. Parkash has over 30 years of experience in Specialty Chemicals, Agro-Chemicals, and Pharma APIs.
The appointment is subject to shareholder approval through a Special Resolution.
Mr. Parkash also serves as a Non-Executive Director on the Board of Alembic Limited.
👀 What to Watch
Investors should view this as a routine leadership transition; the internal promotion of an industry veteran suggests stability in operational management. No immediate action is required, but shareholders should look for the upcoming Special Resolution to formalize the appointment.
Paushak Ltd Q3 FY26 PAT Drops 59% YoY to ₹6.17 Cr; Revenue Declines to ₹48.8 Cr
Paushak Limited reported a weak performance for the quarter ended December 31, 2025, with Net Profit (PAT) falling 59.5% YoY to ₹6.17 crore from ₹15.26 crore. Revenue from operations saw a marginal decline YoY to ₹48.80 crore but a significant 17% drop on a sequential (QoQ) basis. Profitability was severely impacted by a sharp reduction in Other Income, which fell from ₹6.31 crore to just ₹0.97 crore YoY. Additionally, the company made a provision of ₹1.01 crore towards new Labour Code implementations.
Key Highlights
Revenue from Operations stood at ₹48.80 crore, down from ₹58.78 crore in the previous quarter (QoQ).
Net Profit (PAT) declined sharply to ₹6.17 crore compared to ₹15.26 crore in Q3 FY25.
Other Income dropped significantly to ₹0.97 crore from ₹6.31 crore in the corresponding quarter last year.
Restated EPS for the quarter fell to ₹2.50 from ₹6.19 YoY, accounting for the 3:1 bonus issue and stock split.
The company's equity shares were successfully listed on the National Stock Exchange (NSE) effective December 1, 2025.
👀 What to Watch
Investors should exercise caution as the company faces both sequential and year-on-year declines in top-line and bottom-line performance. The significant drop in other income and the impact of new labour provisions warrant a closer look at the core operating margins in upcoming quarters.
Paushak Q3 PAT Drops 60% YoY to ₹6.17 Cr; Revenue Declines 17% QoQ
Paushak Limited reported a significant 59.6% YoY decline in Net Profit to ₹6.17 crore for Q3 FY26, down from ₹15.26 crore. Revenue from operations also faced pressure, falling 17% sequentially to ₹48.8 crore compared to the previous quarter. The company's margins were squeezed by rising employee costs, including a one-time provision of ₹1.01 crore for new labour codes. During the quarter, the company completed a 3:1 bonus issue and stock split, and successfully listed its shares on the NSE.
Key Highlights
Net Profit (PAT) plummeted 59.6% YoY to ₹6.17 crore from ₹15.26 crore in the previous year.
Revenue from operations stood at ₹48.8 crore, a 17% decline from ₹58.78 crore in Q2 FY26.
Employee benefit expenses increased to ₹10.90 crore, including a ₹1.01 crore provision for new Labour Codes.
Restated EPS for the quarter fell to ₹2.50 compared to ₹6.19 in the same period last year.
The company successfully listed on the National Stock Exchange (NSE) on December 1, 2025.
👀 What to Watch
The sharp decline in profitability and sequential revenue drop are concerning; investors should wait for signs of margin recovery before increasing exposure. While the NSE listing improves liquidity, the underlying fundamental performance remains under pressure.
Paushak Ltd Commences Phased Production at New Rs 175 Cr Multi-Purpose Plant
Paushak Limited has initiated the phased commissioning of its new Multi-Purpose Plant for chemical derivatives and associated infrastructure. The project involves a significant investment of approximately Rs 175 crore, which is being funded through a combination of internal accruals and borrowings. This expansion is strategically designed to replace legacy manufacturing facilities and provide much-needed capacity enhancement, as existing facilities are currently optimally utilized. The full capacity from this expansion is expected to be added progressively over the next 12 months.
Key Highlights
Investment of approximately Rs 175 crore in a new Multi-Purpose Plant for derivatives
Commissioning process started in a phased manner to ensure smooth operational transition
Project rationale includes both replacement of legacy facilities and significant capacity enhancement
Proposed capacity to be fully integrated and added over the next 12 months
Financing structured through a mix of internal accruals and external borrowings
👀 What to Watch
Investors should view this as a significant growth catalyst that addresses current capacity constraints. Monitor the quarterly revenue trajectory over the next year to track the successful ramp-up of this new facility.
Paushak Limited CRISIL Rating Reaffirmed; Bank Facilities Enhanced to Rs 145 Crore
CRISIL Ratings has reaffirmed Paushak Limited's long-term credit rating at 'CRISIL A/Stable' and assigned a short-term rating of 'CRISIL A1'. The total rated bank loan facilities have been significantly increased from Rs 40 crore to Rs 145 crore. This enhancement includes a new term loan of Rs 70 crore and expanded working capital facilities totaling Rs 75 crore. The reaffirmation of the 'Stable' outlook indicates the company's maintained creditworthiness despite the higher debt capacity.
Key Highlights
Long-term credit rating reaffirmed at 'CRISIL A/Stable' by CRISIL Ratings.
Short-term credit rating of 'CRISIL A1' assigned for working capital facilities.
Total bank loan facilities rated increased from Rs 40 crore to Rs 145 crore.
New facilities include a Rs 70 crore Term Loan and Rs 75 crore in total Working Capital limits.
The rating assignment covers both existing and proposed enhanced credit limits.
👀 What to Watch
The reaffirmation of a strong credit rating alongside a significant increase in borrowing limits suggests the company is well-positioned for expansion. Investors should monitor the deployment of the new Rs 70 crore term loan for capital expenditure or growth initiatives.
